$ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Healthcare
Sector
Biotechnology
Industry
Matthew Gline
CEO
908
Employees
$37.37
Current Price
$19.67B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $24,160,401.83 | 664,826 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 4 | $24,160,401.83 | 664,826 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $31,150,401.83 | 864,826 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 28 | $227,998,148.47 | 6,607,065 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 28 | $227,998,148.47 | 6,607,065 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Sukhatme Mayukh Director | Sale | 31,801 | $37.18 | $1,182,361.18 | View Details |
| Aug 17, 2026 | Sukhatme Mayukh Director | Sale | 284,707 | $36.25 | $10,320,628.75 | View Details |
| Aug 18, 2026 | Sukhatme Mayukh Director | Sale | 105,141 | $36.59 | $3,847,109.19 | View Details |
| Aug 14, 2026 | Sukhatme Mayukh Director | Sale | 243,177 | $36.23 | $8,810,302.71 | View Details |
| Jul 27, 2026 | Venker Eric President&Immunovant CEO | Sale | 200,000 | $34.95 | $6,990,000.00 | View Details |
| Jun 30, 2026 | Fitzgerald Meghan Director | Sale | 10,000 | $34.90 | $349,000.00 | View Details |
| Jun 29, 2026 | Epperly Melissa B, Director | Sale | 2,748 | $34.71 | $95,383.08 | View Details |
| Jun 29, 2026 | Epperly Melissa B, Director | Sale | 15,002 | $34.32 | $514,868.64 | View Details |
| Jun 26, 2026 | MANCHESTER KEITH S Director | Sale | 325,000 | $34.07 | $11,072,750.00 | View Details |
| Jun 30, 2026 | MANCHESTER KEITH S Director | Sale | 12,380 | $35.28 | $436,766.40 | View Details |
| Jun 29, 2026 | MANCHESTER KEITH S Director | Sale | 200,000 | $34.44 | $6,888,000.00 | View Details |
| Jun 30, 2026 | MANCHESTER KEITH S Director | Sale | 200,000 | $35.45 | $7,090,000.00 | View Details |
| Jun 26, 2026 | MANCHESTER KEITH S Director | Sale | 300,783 | $33.92 | $10,202,559.36 | View Details |
| Jun 29, 2026 | MANCHESTER KEITH S Director | Sale | 600,000 | $34.59 | $20,754,000.00 | View Details |
| Jun 26, 2026 | Gold Daniel Allen Director | Sale | 325,000 | $34.07 | $11,072,750.00 | View Details |
| Jun 26, 2026 | Gold Daniel Allen Director | Sale | 300,783 | $33.92 | $10,202,559.36 | View Details |
| Jun 29, 2026 | Gold Daniel Allen Director | Sale | 200,000 | $34.44 | $6,888,000.00 | View Details |
| Jun 29, 2026 | Gold Daniel Allen Director | Sale | 600,000 | $34.59 | $20,754,000.00 | View Details |
| Jun 30, 2026 | Gold Daniel Allen Director | Sale | 12,380 | $35.28 | $436,766.40 | View Details |
| Jun 29, 2026 | QVT Financial LP Director by Deputization | Sale | 200,000 | $34.44 | $6,888,000.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history